NASDAQ:KNSA

Kiniksa Pharmaceuticals . Class A Stock Insider Trading

Healthcare > Biotechnology

Buy KNSA

*Your capital is at risk

$47.85

+0.93 (+1.98%)

At Close: Jun 03, 2026

Kiniksa Pharmaceuticals . Class A Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -77.00. In total, the insiders bought 2.75M and sold 1.56M KNSA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-77.00
● Buy	2.75M shares
● Sell	1.56M shares
76% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -77. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 06, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	7 278 Value: $75.4K
Apr 06, 2026 Sell	Class A Ordinary Share S-Sale	Patel Sanj K Chairman & CEO	CEO / President	7 278 Value: $364.0K
Apr 06, 2026 Buy	Share Option M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	7 278 Value: $75.4K
Apr 06, 2026 Buy	Class A Ordinary Share M-Exempt	Quart Barry D Director	Director	6 901 Value: $98.9K
Apr 01, 2026 Buy	Restricted Share Unit M-Exempt	Ragosa Mark Chief Financial Officer	C-Suite Officer	1 846 Value: $88.8K
Apr 01, 2026 Buy	Restricted Share Unit M-Exempt	Ragosa Mark Chief Financial Officer	C-Suite Officer	1 750 Value: $84.2K
Apr 01, 2026 Buy	Class A Ordinary Share M-Exempt	Patel Sanj K Chairman & CEO	CEO / President	21 327 Value: $1.03M
Apr 01, 2026 Buy	Performance Share Unit A-Award	Patel Sanj K Chairman & CEO	CEO / President	60 100 Value: $2.89M
Apr 01, 2026 Buy	Restricted Share Unit A-Award	Patel Sanj K Chairman & CEO	CEO / President	30 050 Value: $1.45M
Apr 01, 2026 Buy	Restricted Share Unit M-Exempt	Tessari Eben Chief Strategy Officer	Officer	2 457 Value: $118.3K
Apr 01, 2026 Buy	Restricted Share Unit M-Exempt	Tessari Eben Chief Strategy Officer	Officer	1 745 Value: $84.0K
Apr 01, 2026 Buy	Share Option A-Award	Ragosa Mark Chief Financial Officer	C-Suite Officer	31 150 Value: $1.50M
Apr 01, 2026 Buy	Class A Ordinary Share M-Exempt	Ragosa Mark Chief Financial Officer	C-Suite Officer	5 187 Value: $249.7K
Apr 01, 2026 Sell	Class A Ordinary Share F-InKind	Ragosa Mark Chief Financial Officer	C-Suite Officer	2 510 Value: $120.8K
Apr 01, 2026 Buy	Restricted Share Unit A-Award	Ragosa Mark Chief Financial Officer	C-Suite Officer	7 800 Value: $375.4K
Apr 01, 2026 Buy	Performance Share Unit A-Award	Ragosa Mark Chief Financial Officer	C-Suite Officer	15 600 Value: $750.8K
Apr 01, 2026 Buy	Restricted Share Unit M-Exempt	Tessari Eben Chief Strategy Officer	Officer	1 773 Value: $85.3K
Apr 01, 2026 Buy	Restricted Share Unit A-Award	Tessari Eben Chief Strategy Officer	Officer	8 300 Value: $399.5K
Apr 01, 2026 Sell	Class A Ordinary Share F-InKind	Patel Sanj K Chairman & CEO	CEO / President	10 313 Value: $496.4K
Apr 01, 2026 Buy	Share Option A-Award	Patel Sanj K Chairman & CEO	CEO / President	120 150 Value: $5.78M
Apr 01, 2026 Buy	Restricted Share Unit M-Exempt	Ragosa Mark Chief Financial Officer	C-Suite Officer	1 591 Value: $76.6K
Apr 01, 2026 Buy	Share Option A-Award	Tessari Eben Chief Strategy Officer	Officer	33 200 Value: $1.60M
Apr 01, 2026 Buy	Class A Ordinary Share M-Exempt	Tessari Eben Chief Strategy Officer	Officer	5 975 Value: $287.6K
Apr 01, 2026 Sell	Class A Ordinary Share F-InKind	Tessari Eben Chief Strategy Officer	Officer	1 756 Value: $84.5K
Jan 15, 2026 Buy	Class A Ordinary Share A-Award	Tessari Eben Chief Strategy Officer	Officer	365 Value: $9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KINIKSA PHARMACEUTICALS LTD. CLASS A

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...

Read Full Profile Here